SVRA
Savara Inc.
Biotechnology
Market Cap$904M
5Y Perf.+114.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SVRA vs MNKD
Revenue, margins, valuation, and 5-year total return — side by side.
MNKD
MannKind Corporation
Biotechnology
Market Cap$1.09B
5Y Perf.+133.1%
SVRA vs MNKD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SVRA | MNKD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $904M | $1.09B |
| Revenue (TTM) | $0.00 | $361M |
| Net Income (TTM) | $-116M | $-24M |
| Gross Margin | — | 79.3% |
| Operating Margin | — | 4.1% |
| Forward P/E | — | 176.0x |
| Total Debt | $27M | $473M |
| Cash & Equiv. | $15M | $75M |
SVRA vs MNKD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SVRA
MNKD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Savara Inc. (SVRA) | 100 | 214.3 | +114.3% |
| MannKind Corporation (MNKD) | 100 | 233.1 | +133.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SVRA vs MNKD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNKD leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Savara Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SVRA
Savara Inc.
The Growth Play
SVRA is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth -45.5%
- -40.3% 10Y total return vs MNKD's -46.7%
- 3.0% margin vs MNKD's -6.6%
Best for: growth exposure and long-term compounding
MNKD
MannKind Corporation
The Income Pick
MNKD carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.09
- Lower volatility, beta 1.09, current ratio 1.70x
- Beta 1.09, current ratio 1.70x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNKD | 22.2% revenue growth vs SVRA's -39.5% |
| Quality / Margins | SVRA | 3.0% margin vs MNKD's -6.6% |
| Stability / Safety | MNKD | Beta 1.09 vs SVRA's 1.10 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SVRA | +62.4% vs MNKD's -24.0% |
| Efficiency (ROA) | MNKD | -3.9% ROA vs SVRA's -82.1%, ROIC 21.6% vs -47.9% |
SVRA vs MNKD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
SVRA vs MNKD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSVRALAGGINGMNKD
MNKDMannKind Corporation
1leads
SVRASavara Inc.
3leads
6 Total Categories
CATEGORYLEADERvs MNKDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SVRA1/1
Valuation MetricsMultiples, price ratios, and targets
SVRA1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNKD4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
SVRA6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SVRA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MNKD and SVRA operate at a comparable scale, with $361M and $0 in trailing revenue.
| Metric | SVRASavara Inc. | MNKDMannKind Corporat… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $361M |
| EBITDAEarnings before interest/tax | -$121M | $25M |
| Net IncomeAfter-tax profit | -$116M | -$24M |
| Free Cash FlowCash after capex | -$99M | $13M |
| Gross MarginGross profit ÷ Revenue | — | +79.3% |
| Operating MarginEBIT ÷ Revenue | — | +4.1% |
| Net MarginNet income ÷ Revenue | — | -6.6% |
| FCF MarginFCF ÷ Revenue | — | +3.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +15.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -27.3% | -2.2% |
SVRA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
SVRA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | SVRASavara Inc. | MNKDMannKind Corporat… |
|---|---|---|
| Market CapShares × price | $904M | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $916M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -10.90x | 176.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 29.09x |
| Price / SalesMarket cap ÷ Revenue | — | 3.12x |
| Price / BookPrice ÷ Book value/share | 6.05x | — |
| Price / FCFMarket cap ÷ FCF | — | 79.44x |
SVRA leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
MNKD leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), MNKD scores 4/9 vs SVRA's 2/9, reflecting mixed financial health.
| Metric | SVRASavara Inc. | MNKDMannKind Corporat… |
|---|---|---|
| ROE (TTM)Return on equity | -122.5% | — |
| ROA (TTM)Return on assets | -82.1% | -3.9% |
| ROICReturn on invested capital | -47.9% | +21.6% |
| ROCEReturn on capital employed | -56.5% | +8.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.16x | — |
| Net DebtTotal debt minus cash | $12M | $399M |
| Cash & Equiv.Liquid assets | $15M | $75M |
| Total DebtShort + long-term debt | $27M | $473M |
| Interest CoverageEBIT ÷ Interest expense | — | 0.75x |
MNKD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
SVRA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SVRA five years ago would be worth $32,893 today (with dividends reinvested), compared to $8,649 for MNKD. Over the past 12 months, SVRA leads with a +62.4% total return vs MNKD's -24.0%. The 3-year compound annual growth rate (CAGR) favors SVRA at 38.7% vs MNKD's -3.2% — a key indicator of consistent wealth creation.
| Metric | SVRASavara Inc. | MNKDMannKind Corporat… |
|---|---|---|
| YTD ReturnYear-to-date | -7.3% | -37.1% |
| 1-Year ReturnPast 12 months | +62.4% | -24.0% |
| 3-Year ReturnCumulative with dividends | +166.8% | -9.3% |
| 5-Year ReturnCumulative with dividends | +228.9% | -13.5% |
| 10-Year ReturnCumulative with dividends | -40.3% | -46.7% |
| CAGR (3Y)Annualised 3-year return | +38.7% | -3.2% |
SVRA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SVRA and MNKD each lead in 1 of 2 comparable metrics.
Risk & Volatility
MNKD is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than SVRA's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SVRA currently trades 74.7% from its 52-week high vs MNKD's 54.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SVRASavara Inc. | MNKDMannKind Corporat… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 1.09x |
| 52-Week HighHighest price in past year | $7.00 | $6.51 |
| 52-Week LowLowest price in past year | $1.89 | $2.23 |
| % of 52W HighCurrent price vs 52-week peak | +74.7% | +54.1% |
| RSI (14)Momentum oscillator 0–100 | 45.7 | 73.8 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 6.0M |
Evenly matched — SVRA and MNKD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SVRA as "Buy" and MNKD as "Buy". Consensus price targets imply 134.4% upside for MNKD (target: $8) vs 91.2% for SVRA (target: $10).
| Metric | SVRASavara Inc. | MNKDMannKind Corporat… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $10.00 | $8.25 |
| # AnalystsCovering analysts | 11 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SVRA leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). MNKD leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallSavara Inc. (SVRA)Leads 3 of 6 categories
Loading custom metrics...
SVRA vs MNKD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SVRA or MNKD a better buy right now?
MannKind Corporation (MNKD) offers the better valuation at 176.
0x trailing P/E, making it the more compelling value choice. Analysts rate Savara Inc. (SVRA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SVRA or MNKD?
Over the past 5 years, Savara Inc.
(SVRA) delivered a total return of +228. 9%, compared to -13. 5% for MannKind Corporation (MNKD). Over 10 years, the gap is even starker: SVRA returned -40. 3% versus MNKD's -46. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SVRA or MNKD?
By beta (market sensitivity over 5 years), MannKind Corporation (MNKD) is the lower-risk stock at 1.
09β versus Savara Inc. 's 1. 10β — meaning SVRA is approximately 1% more volatile than MNKD relative to the S&P 500.
04Which is growing faster — SVRA or MNKD?
On earnings-per-share growth, the picture is similar: Savara Inc.
grew EPS -45. 5% year-over-year, compared to -79. 4% for MannKind Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SVRA or MNKD?
MannKind Corporation (MNKD) is the more profitable company, earning 1.
7% net margin versus 0. 0% for Savara Inc. — meaning it keeps 1. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNKD leads at 11. 1% versus 0. 0% for SVRA. At the gross margin level — before operating expenses — MNKD leads at 82. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SVRA or MNKD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SVRA or MNKD better for a retirement portfolio?
For long-horizon retirement investors, MannKind Corporation (MNKD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
09)). Both have compounded well over 10 years (MNKD: -46. 7%, SVRA: -40. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SVRA and MNKD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SVRA is a small-cap quality compounder stock; MNKD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.